Streetbeat News

Regulatory

VIGL

The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase 1 trial of VG-3927 after the company submitted a complete response. Full data from the trial is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:09 am

CGEM

Cullinan Therapeutics (NASDAQ:CGEM) has received approval in Australia to begin a global Phase 1 trial for its SLE treatment, CLN-978. This novel therapy aims to provide a more effective treatment option for SLE, a condition affecting 430,000 people globally.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:07 am

ACRS

Aclaris Therapeutics has initiated a Phase 2a trial for ATI-2138, targeting moderate to severe atopic dermatitis. The trial will assess safety, tolerability, and efficacy over 12 weeks with 15 subjects in the US. Results are expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:04 am

BSX

Boston Scientific has received FDA approval to expand the indication for its INGEVITY+ pacing leads to include conduction system pacing of the left bundle branch area. This approval could enhance the company's market position in cardiac pacing solutions.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:02 am

CMP

Compass Minerals is in discussions with the U.S. Forest Service to evaluate and test non-magnesium chloride-based aerial fire retardants, exploring various alternatives for Fortress North America.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:10 am

TSLA

VLVCY

A study by the Insurance Institute for Highway Safety and MIT's AgeLab found that drivers using Tesla's Autopilot and Volvo's Pilot Assist tend to multitask and pay less attention to the road. This highlights the need for more robust safeguards in partial automation systems.

Portfolio Pulse from Anan Ashraf

September 17, 2024 | 9:31 am

ORCL

Oracle's Larry Ellison predicts AI will enable constant surveillance of police officers, potentially reducing crime but raising concerns about bias. This discussion is part of a broader conversation on AI's societal impact.

Portfolio Pulse from Benzinga Neuro

September 17, 2024 | 8:12 am

META

Meta Platforms Inc (NASDAQ:META) has globally banned Russian state media outlets like RT and Rossiya Segodnya from its platforms to counter foreign influence. This move is part of Meta's broader efforts to combat disinformation and covert influence operations.

Portfolio Pulse from Benzinga Neuro

September 17, 2024 | 6:57 am

ASML

NVDA

The U.S. and Japan are finalizing a deal to limit chip technology exports to China, impacting companies like ASML and Nvidia. The move aims to close loopholes in existing rules and align export controls among the U.S., Japan, and the Netherlands. China opposes these measures and is boosting its own chip manufacturing capabilities.

Portfolio Pulse from Benzinga Neuro

September 17, 2024 | 6:25 am

TSLA

Tesla plans to start delivering its Cybertruck in Canada by late October, following regulatory clearances received in July. The Cybertruck, previously limited to the U.S., will be available in Canada with prices starting at C$137,990.

Portfolio Pulse from Anan Ashraf

September 17, 2024 | 6:05 am